A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Registration Number
- NCT03503604
- Lead Sponsor
- SuZhou Stainwei Biotech Inc.
- Brief Summary
hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor (VEGF). hPV19 binds to human VEGF with unique binding site on VEGF different from that of Bevacizumab(Avastin) and inhibits the binding of VEGF to it's receptors, VEGF-R1 and VEGF-R2. By preventing VEGF binding to its receptors, growth of tumor blood vessels are inhibited and tumor growth prevented or slowed. In this study we are investigating the tolerability, safety, pharmacokinetics and anti-tumor activity of hPV19 in combination with chemotherapy in patients with solid tumors. hPV19 will give to patients by intravenous(i.v.) infusion with a single and multiple doses.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 18
- Confirmed malignity
- Measurable disease
- Performance status 2 or less(ECOG)
- Life expectancy ≥3 months
- hepatitis C virus (HCV), or HIV antibody positive
- Previously received anti-VEGF mAb or fusion-protein drugs within 28 days nearly
- Evidence of serious infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description group 1 hPV19 mAb hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin) group 1 5-Fluorouracil hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin) group 1 Leucovorin hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin) group 2 hPV19 mAb hPV19 mAb plus paclitaxel/carboplatin group 2 Paclitaxel hPV19 mAb plus paclitaxel/carboplatin group 2 Carboplatin hPV19 mAb plus paclitaxel/carboplatin group 3 hPV19 mAb hPV19 mAb plus gemcitabine/carboplatin group 3 Carboplatin hPV19 mAb plus gemcitabine/carboplatin group 4 hPV19 mAb hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin) group 4 Irinotecan hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin) group 1 Oxaliplatin hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin) group 3 Gemcitabine hPV19 mAb plus gemcitabine/carboplatin group 4 Leucovorin hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin) group 4 5-Fluorouracil hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
- Primary Outcome Measures
Name Time Method Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period during the first 21 days DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03) with any one of the following:
1. Grade 4 neutropenia ≥7 days; febrile neutropenia; grade 4 anemia; grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding;
2. ≥ grade 3 nonhematologic toxicity with the exception of nausea, vomiting, diarrhea, dehydration or electrolyte abnormalities that resolved to a lower grade with maximum supportive treatment within 3 days;
3. ≥Grade 3 hypertension that cannot resolved to a lower grade with supportive treatment within 2 weeks or uncontrolled hypertension;
4. Urine protein ≥3.5 grams/24 hours and cannot resolved to \< 1.0 grams/24 hours within 2 weeks;
5. Gastrointestinal perforation: symptoms, signs and imaging evidence of abdominal pain require surgical treatment;
6. Grade 3 or 4 arterial thromboembolism, including stroke and myocardial infarction;Number of Participants With hPV19 Drug-Related Adverse Events or Serious Adverse Events Baseline to the last dose plus 28 days. Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to hPV19. Events related to chemotherapy were reported separately.
- Secondary Outcome Measures
Name Time Method Half Life (t1/2) of hPV19 Single dose(Cycle 1)：2h before administered, after administered 10min±5min、4h±30min、24h±1h、168h±1h、336h±1h. Other cycles: 2h before administered and after administration 10min±5min. t1/2 is the time required for the plasma/serum concentration to decrease 50%
Area Under the Curve (AUC) of hPV19 Single dose(Cycle 1)：2h before administered, after administered 10min±5min、4h±30min、24h±1h、168h±1h、336h±1h. Other cycles: 2h before administered and after administration 10min±5min. Clearance (CL) of hPV19 Single dose(Cycle 1)：2h before administered, after administered 10min±5min、4h±30min、24h±1h、168h±1h、336h±1h. Other cycles: 2h before administered and after administration 10min±5min. Number of Participants With Serum Anti-hPV19 Antibodies (Immunogenicity) before Single dose; Day 21 of 21-day DLT assessment period; Every 8 or 9 weeks after 21-day DLT assessment period. Maximum Concentration (Cmax) of hPV19 Single dose(Cycle 1)：2h before administered; after administered 10min±5min、4h±30min、24h±1h、168h±1h、336h±1h. Other cycles: 2h before administered and after administration 10min±5min. Steady State Volume of Distribution (Vss) of hPV19 Single dose(Cycle 1)：2h before administered; after administered 10min±5min、4h±30min、24h±1h、168h±1h、336h±1h. Other cycles: 2h before administered and after administration 10min±5min. Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum
Best Overall Response [Anti-Tumor Activity of hPV19 Plus Chemotherapy] Up to six months after 1st treatment or until progression of disease (PD) Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria.
Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
Trial Locations
- Locations (1)
Shanghai East Hospital
🇨🇳Shanghai, Shanghai, China